Panel Discussion: Positioning Microbiome Science & Clinical Translation to Meet Mainstream VC Investment Criteria Early

• Defining core investment checklists used by generalist biotech VCs to assess microbiome opportunities, enabling alignment of narratives with decision drivers
• Diagnosing causes of investor skepticism following early company failures to reposition data packages, risk profiles, and timelines for renewed confidence
• Attracting non-specialist venture investors by translating complex biology into clear value propositions and commercial milestones to expand the capital pool

Speakers:

Vanessa Ridaura

Senior Program Officer - Microbiome Products

The Gates Foundation

Sathya Janardhanan

Venture Partner

Ecphora Capital

Henry Haiser

Operating Partner

Corundum Systems Biology

Denise Kelly

Investment Advisor

Seventure Partners